Panbela announces issuance of new patent in chile for claims of a novel process for the production of flynpovi

Minneapolis, sept. 05, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an issue notification for the chilean patent 1157-2018 titled “eflornithine and sulindac, fixed dose combination formulation”.
PBLA Ratings Summary
PBLA Quant Ranking